## Paul O Collinson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5746098/publications.pdf

Version: 2024-02-01

145 papers 8,206 citations

39 h-index 48187 88 g-index

148 all docs

148
docs citations

times ranked

148

6860 citing authors

#	Article	IF	Citations
1	Rapid diagnostic strategies using high sensitivity troponin assays: what is the evidence and how should they be implemented?. Annals of Clinical Biochemistry, 2023, 60, 37-45.	0.8	1
2	Diagnostic Performance of Novel Troponin Algorithms for the Rule-Out of Non-ST-Elevation Acute Coronary Syndrome. Clinical Chemistry, 2022, 68, 291-302.	1.5	6
3	Diagnostic accuracy of a high-sensitivity troponin I assay and external validation of 0/3 h rule out strategies. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 127-136.	0.4	3
4	Adding stress biomarkers to high-sensitivity cardiac troponin for rapid non-ST-elevation myocardial infarction rule-out protocols. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 201-212.	0.4	9
5	Point-of-care testing with high-sensitivity cardiac troponin assays: the challenges and opportunities. Emergency Medicine Journal, 2022, 39, 861-866.	0.4	18
6	High-sensitivity cardiac troponin and the diagnosis of myocardial infarction in patients with kidney impairment. Kidney International, 2022, 102, 149-159.	2.6	9
7	Analytical Considerations in Deriving 99th Percentile Upper Reference Limits for High-Sensitivity Cardiac Troponin Assays: Educational Recommendations from the IFCC Committee on Clinical Application of Cardiac Bio-Markers. Clinical Chemistry, 2022, 68, 1022-1030.	1.5	26
8	Finding acute coronary syndrome with serial troponin testing for rapid assessment of cardiac ischemic symptoms (FAST-TRAC): a study protocol. Clinical and Experimental Emergency Medicine, 2022, 9, 140-145.	0.5	4
9	Caveat emptor– hidden pitfalls in defining the 99th percentile of cardiac troponin assays. Clinical Chemistry and Laboratory Medicine, 2021, 59, e345-e347.	1.4	1
10	Getting Cardiac Troponin Right: Appraisal of the 2020 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation by the International Federation of Clinical Chemistry and Laboratory Medicine Committee on Clinical Applications of Cardiac Bio-Markers. Clinical Chemistry, 2021, 67, 730-735.	1.5	28
11	High sensitivity troponin, analytical advantages, clinical benefits and clinical challenges – An update. Clinical Biochemistry, 2021, 91, 1-8.	0.8	3
12	High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled Trial. Circulation, 2021, 143, 2214-2224.	1.6	80
13	How Well Do Laboratories Adhere to Recommended Guidelines for Cardiac Biomarkers Management in Europe? The CArdiac MARker Guideline Uptake in Europe (CAMARGUE) Study of the European Federation of Laboratory Medicine Task Group on Cardiac Markers. Clinical Chemistry, 2021, 67, 1144-1152.	1.5	7
14	Biomarker Testing Considerations in the Evaluation and Management of Patients With Heart Failure: Perspectives From the International Federation of Clinical Chemistry and Laboratory Medicine Committee. Journal of Cardiac Failure, 2021, 27, 1456-1461.	0.7	1
15	Cardiac Troponin Thresholds and Kinetics to Differentiate Myocardial Injury and Myocardial Infarction. Circulation, 2021, 144, 528-538.	1.6	39
16	Implementation of High-Sensitivity and Point-of-Care Cardiac Troponin Assays into Practice: Some Different Thoughts. Clinical Chemistry, 2021, 67, 70-78.	1.5	24
17	Optimizing the Use of High-Sensitivity Troponin Assays for the Early Rule-out of Myocardial Infarction in Patients Presenting with Chest Pain: A Systematic Review. Clinical Chemistry, 2021, 67, 237-244.	1.5	17
18	Commentary on Gastrointestinal Symptoms Followed by Shock in a Febrile 7-Year-Old Child during the COVID-19 Pandemic. Clinical Chemistry, 2021, 67, 58-59.	1.5	0

#	Article	IF	Citations
19	High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction. Circulation, 2020, 141, 161-171.	1.6	124
20	Use of troponins in clinical practice: Evidence in favour of use of troponins in clinical practice. Heart, 2020, 106, 253-255.	1.2	4
21	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clinical Chemistry and Laboratory Medicine, 2020, 58, 496-517.	1.4	119
22	Comparison of four decision aids for the early diagnosis of acute coronary syndromes in the emergency department. Emergency Medicine Journal, 2020, 37, 8-13.	0.4	40
23	Cardiac Troponin Assays With Improved Analytical Quality: A Tradeâ€Off Between Enhanced Diagnostic Performance and Reduced Longâ€Term Prognostic Value. Journal of the American Heart Association, 2020, 9, e017465.	1.6	7
24	99th Percentile Upper-Reference Limit of Cardiac Troponin and the Diagnosis of Acute Myocardial Infarction. Clinical Chemistry, 2020, 66, 1167-1180.	1.5	22
25	Admission troponin measurement for the diagnosis of myocardial infarction: the search for one and done continues. European Heart Journal Quality of Care & Dinical Outcomes, 2020, 6, 184-185.	1.8	0
26	Cardiac biomarker measurement by point of care testing – Development, rationale, current state and future developments. Clinica Chimica Acta, 2020, 508, 234-239.	0.5	14
27	False-positive troponin elevation due to an immunoglobulin-G-cardiac troponin T complex: a case report. European Heart Journal - Case Reports, 2020, 4, 1-5.	0.3	14
28	How well do laboratories adhere to recommended guidelines for dyslipidaemia management in Europe? The CArdiac MARker Guideline Uptake in Europe (CAMARGUE) study. Clinica Chimica Acta, 2020, 508, 267-272.	0.5	13
29	Cardiac Troponin by Point-of-CareÂTesting. Journal of the American College of Cardiology, 2020, 75, 1125-1127.	1.2	1
30	Single test rule-out of acute myocardial infarction using the limit of detection of a new high-sensitivity troponin I assay. Clinical Biochemistry, 2020, 78, 4-9.	0.8	18
31	Interanalyzer Analytical Variation of a High-Sensitivity Cardiac Troponin T Assay Can Exceed the Cutoff of the European Society of Cardiology 1-Hour Algorithm for Ruling Out Non–ST-Segment Elevated Myocardial Infarction. Clinical Chemistry, 2020, 66, 495-496.	1.5	9
32	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. Atherosclerosis, 2020, 294, 46-61.	0.4	137
33	Update on current practice in laboratory medicine in respect of natriuretic peptide testing for heart failure diagnosis and management in Europe. The CARdiac MArker guideline Uptake in Europe (CARMAGUE) study. Clinica Chimica Acta, 2020, 511, 59-66.	0.5	6
34	Unexpected Troponin Elevation in a Patient Treated with Atorvastatin. journal of applied laboratory medicine, The, 2020, 5, 798-801.	0.6	5
35	Cardiac biomarkers by point-of-care testing – back to the future?. Journal of Laboratory Medicine, 2020, 44, 89-95.	1.1	3
36	Biotin interference in cardiac troponin immunoassay $\hat{a} \in \text{``where the wild things are?. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1769-1771.}$	1.4	0

#	Article	IF	CITATIONS
37	Educational Recommendations on Selected Analytical and Clinical Aspects of Natriuretic Peptides with a Focus on Heart Failure: A Report from the IFCC Committee on Clinical Applications of Cardiac Bio-Markers. Clinical Chemistry, 2019, 65, 1221-1227.	1.5	21
38	Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome. Journal of the American College of Cardiology, 2019, 74, 2032-2043.	1.2	84
39	Troponin in Suspected CoronaryÂArteryÂDisease. Journal of the American College of Cardiology, 2019, 73, 261-263.	1.2	2
40	Aiming toWards Evidence baSed inTerpretation of Cardiac biOmarkers in patients pResenting with chest pain-the WESTCOR study: study design. Scandinavian Cardiovascular Journal, 2019, 53, 280-285.	0.4	9
41	A Few Steps Closer to Optimizing Pseudohyperkalemia Detection. journal of applied laboratory medicine, The, 2019, 3, 919-921.	0.6	4
42	How Does the Analytical Quality of the High-Sensitivity Cardiac Troponin T Assay Affect the ESC Rule Out Algorithm for NSTEMI?. Clinical Chemistry, 2019, 65, 494-496.	1.5	14
43	High sensitivity, contemporary and point-of-care cardiac troponin assays: educational aids developed by the IFCC Committee on Clinical Application of Cardiac Bio-Markers. Clinical Chemistry and Laboratory Medicine, 2019, 57, 623-632.	1.4	76
44	Cardiac troponin and natriuretic peptide analytical interferences from hemolysis and biotin: educational aids from the IFCC Committee on Cardiac Biomarkers (IFCC C-CB). Clinical Chemistry and Laboratory Medicine, 2019, 57, 633-640.	1.4	33
45	Too much of a good thing – the over requesting of cardiac troponin. Annals of Clinical Biochemistry, 2018, 55, 522-524.	0.8	0
46	Troponin, delta change and the evolution of cardiac biomarkers – back to the future (again). Annals of Clinical Biochemistry, 2018, 55, 626-629.	0.8	2
47	High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. Lancet, The, 2018, 392, 919-928.	6.3	263
48	Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection. Annals of Internal Medicine, 2017, 166, 715.	2.0	231
49	Early diagnosis of acute coronary syndrome. European Heart Journal, 2017, 38, 3049-3055.	1.0	50
50	Cardiac troponins: from myocardial infarction to chronic disease. Cardiovascular Research, 2017, 113, 1708-1718.	1.8	322
51	Laboratory Medicine is Faced with the Evolution of Medical Practice. Journal of Medical Biochemistry, 2017, 36, 211-215.	0.7	28
52	In Search of Normality for Cardiac Biomarkers in Cardiovascular Disease Detection. journal of applied laboratory medicine, The, 2017, 1, 605-608.	0.6	0
53	The Dilemma of Finding a Young Patient with a Raised Cholesterol Concentration. journal of applied laboratory medicine, The, 2017, 1, 572-575.	0.6	0
54	Are Heart Failure Management Recommendations and Guidelines Followed in Laboratory Medicine in Europe and North America? The Cardiac Marker Guideline Uptake in Europe (CARMAGUE) Study. journal of applied laboratory medicine, The, 2017, 1, 483-493.	0.6	5

#	Article	IF	Citations
55	Heart Fatty Acid Binding Protein for the Diagnosis of Myocardial Ischemia and Infarction. journal of applied laboratory medicine, The, 2017, 1, 702-710.	0.6	О
56	How Well Do Laboratories Adhere to Recommended Clinical Guidelines for the Management of Myocardial Infarction: The CARdiac MArker Guidelines Uptake in Europe Study (CARMAGUE). Clinical Chemistry, 2016, 62, 1264-1271.	1.5	49
57	Should the 1h algorithm for rule in and rule out of acute myocardial infarction be used universally?Sometimes earlier may not be betterBackground, fundamental concepts, and scientific evidence of the high-sensitivity cardiac troponin 0h/1h-algorithm for early rule-out or rule-in of acute myocardial infarction. European Heart Journal. 2016. 37. 3316-3323.	1.0	26
58	High-sensitivity troponin measurements: challenges and opportunities for the laboratory and the clinician. Annals of Clinical Biochemistry, 2016, 53, 191-195.	0.8	2
59	The interaction between systemic inflammation and psychosocial stress in the association with cardiac troponin elevation: A new approach to risk assessment and disease prevention. Preventive Medicine, 2016, 93, 46-52.	1.6	14
60	The effect of multiple analysers on the biochemical diagnosis of myocardial infarction using a contemporary troponin–I assay. Annals of Clinical Biochemistry, 2016, 53, 702-705.	0.8	3
61	Measurement of Lipoproteins: Upping the Game in Characterizing the Lipid Phenotype. journal of applied laboratory medicine, The, 2016, 1, 243-246.	0.6	0
62	High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. BMJ, The, 2015, 350, g7873.	3.0	338
63	The association between fibrinogen reactivity to mental stress and high-sensitivity cardiac troponin T in healthy adults. Psychoneuroendocrinology, 2015, 59, 37-48.	1.3	12
64	The clinical and diagnostic performance characteristics of the high sensitivity Abbott cardiac troponin I assay. Clinical Biochemistry, 2015, 48, 275-281.	0.8	30
65	Type 2 myocardial infarction: the chimaera of cardiology?. Heart, 2015, 101, 1697-1703.	1.2	40
66	Detecting cardiac events – state-of-the-art. Annals of Clinical Biochemistry, 2015, 52, 702-704.	0.8	6
67	Age, sex, and racial influences on the Beckman Coulter AccuTnI+3 99th percentile. Clinica Chimica Acta, 2015, 444, 149-153.	0.5	28
68	The mediation of coronary calcification in the association between risk scores and cardiac troponin T elevation in healthy adults: Is atherosclerosis a good prognostic precursor of coronary disease?. Preventive Medicine, 2015, 77, 150-154.	1.6	4
69	High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet, The, 2015, 386, 2481-2488.	6.3	422
70	Comparison of conventional and high-sensitivity troponin in patients with chest pain: A collaborative meta-analysis. American Heart Journal, 2015, 169, 6-16.e6.	1.2	89
71	Cardiac biomarkers â€" A short biography. Clinical Biochemistry, 2015, 48, 197-200.	0.8	17
72	IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays. Clinical Biochemistry, 2015, 48, 201-203.	0.8	224

#	Article	IF	CITATIONS
73	Evidence and Cost Effectiveness Requirements for Recommending New Biomarkers. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2015, 26, 183-9.	0.7	7
74	Analytical Characteristics of High-Sensitivity Cardiac Troponin Assays. Laboratory Medicine Online, 2014, 4, 55.	0.0	5
75	Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 18-27.	0.4	98
76	Cardiac troponin I but not cardiac troponin T adheres to polysulfone dialyser membranes in an in vitro haemodialysis model: explanation for lower serum cTnI concentrations following dialysis. Open Heart, 2014, 1, e000108.	0.9	20
77	The role of cardiac biomarkers in cardiovascular disease risk assessment. Current Opinion in Cardiology, 2014, 29, 366-371.	0.8	22
78	A prospective study of the impact of serial troponin measurements on the diagnosis of myocardial infarction and hospital and six-month mortality in patients admitted to ICU with non-cardiac diagnoses. Critical Care, 2014, 18, R62.	2.5	37
79	Cardiac biomarkers in heart failure. Clinical Biochemistry, 2014, 47, 327-337.	0.8	48
80	Comparison of contemporary troponin assays with the novel biomarkers, heart fatty acid binding protein and copeptin, for the early confirmation or exclusion of myocardial infarction in patients presenting to the emergency department with chest pain. Heart, 2014, 100, 140-145.	1.2	46
81	Heart failure biomarkers at point-of-care: current utilization and future potential. Expert Review of Molecular Diagnostics, 2014, 14, 185-197.	1.5	13
82	Reference ranges for cardiac troponin in the era of high sensitivity assays. Clinical Biochemistry, 2013, 46, 1629-1630.	0.8	3
83	Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: Current status and future perspectives. American Heart Journal, 2013, 166, 614-621.e1.	1.2	9
84	The Association Between Cortisol Response to Mental Stress and High-Sensitivity Cardiac Troponin T Plasma Concentration in Healthy Adults. Journal of the American College of Cardiology, 2013, 62, 1694-1701.	1.2	81
85	Do laboratories follow heart failure recommendations and guidelines and did we improve? The CARdiac MArker Guideline Uptake in Europe (CARMAGUE). Clinical Chemistry and Laboratory Medicine, 2013, 51, 1301-1306.	1.4	12
86	Comparison between cTnT and CK-MB mass in the diagnosis of myocardial infarction: the response. Heart, 2012, 98, 1326.3-1326.	1.2	1
87	Evidence-Based Laboratory Medicine: How Well Do Laboratories Follow Recommendations and Guidelines? The Cardiac Marker Guideline Uptake in Europe (CARMAGUE) Study. Clinical Chemistry, 2012, 58, 305-306.	1.5	34
88	Republished: Sensitive troponin assays. Postgraduate Medical Journal, 2012, 88, 348-352.	0.9	4
89	Interhospital variation in the RATPAC Trial (Randomised Assessment of Treatment using Panel Assay of) Tj ETQq1	l 1 0.7843	14 rgBT /Ove
90	Influence of Population Selection on the 99th Percentile Reference Value for Cardiac Troponin Assays. Clinical Chemistry, 2012, 58, 219-225.	1.5	230

#	Article	IF	CITATIONS
91	Very early diagnosis of chest pain by point-of-care testing: comparison of the diagnostic efficiency of a panel of cardiac biomarkers compared with troponin measurement alone in the RATPAC trial. Heart, 2012, 98, 312-318.	1.2	46
92	Cost-effectiveness of presentation versus delayed troponin testing for acute myocardial infarction. Heart, 2012, 98, 1498-1503.	1.2	40
93	Analytical Characteristics of High-Sensitivity Cardiac Troponin Assays. Clinical Chemistry, 2012, 58, 54-61.	1.5	730
94	How to use high-sensitivity cardiac troponins in acute cardiac care. European Heart Journal, 2012, 33, 2252-2257.	1.0	666
95	Sensitive troponin assays. Journal of Clinical Pathology, 2011, 64, 845-849.	1.0	13
96	Urinary Measurement of N-Terminal B Type Natriuretic Peptide in Patients With Cardiac Failure - Highway or Byway?. Revista Espanola De Cardiologia (English Ed ), 2011, 64, 355-357.	0.4	1
97	The Randomised Assessment of Treatment using Panel Assay of Cardiac Markers (RATPAC) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Heart, 2011, 97, 190-196.	1.2	116
98	Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary careâ€. European Heart Journal, 2010, 31, 1881-1889.	1.0	103
99	Recommendations for the use of cardiac troponin measurement in acute cardiac care. European Heart Journal, 2010, 31, 2197-2204.	1.0	533
100	Assay Imprecision and 99th-Percentile Reference Value of a High-Sensitivity Cardiac Troponin I Assay. Clinical Chemistry, 2009, 55, 1433-1434.	1.5	36
101	Cardiac markers. British Journal of Hospital Medicine (London, England: 2005), 2009, 70, M84-M87.	0.2	1
102	Natriuretic peptide determinations in critical care medicine: part of routine clinical practice or research test only?. Critical Care, 2009, 13, 105.	2.5	4
103	A pilot survey of the use and implementation of cardiac markers in acute coronary syndrome and heart failure across Europe The CARdiac MArker Guideline Uptake in Europe (CARMAGUE) study. Clinical Chemistry and Laboratory Medicine, 2009, 47, 227-34.	1.4	26
104	Amino-Terminal Pro–B-Type Natriuretic Peptide Testing to Assist the Diagnostic Evaluation of Heart Failure in Symptomatic Primary Care Patients. American Journal of Cardiology, 2008, 101, S25-S28.	0.7	43
105	Cardiac biomarkers in chronic renal disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 104-108.	0.6	4
106	How Well Do Laboratories Follow Guidelines on Cardiac Markers? The Cardiac Marker Guideline Uptake in Europe Study. Clinical Chemistry, 2008, 54, 448-449.	1.5	11
107	Cardiac troponin I measurement using the ACS:180 to predict four-year cardiac event rate. Annals of Clinical Biochemistry, 2008, 45, 184-188.	0.8	3
108	Eculizumab Reduces Pulmonary Hypertension through Inhibition of Hemolysis-Associated Nitric Oxide Consumption in Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2008, 112, 486-486.	0.6	4

#	Article	IF	Citations
109	The role of cardiac troponin measurements. Independent Nurse, 2008, 2008, .	0.0	1
110	Reliability of 6-h troponin T remains unproven. Annals of Clinical Biochemistry, 2007, 44, 94-95.	0.8	1
111	Biomarkers of Cardiovascular Damage. Medical Principles and Practice, 2007, 16, 247-261.	1.1	35
112	Biomarkers of Cardiovascular Damage and Dysfunction—An Overview. Heart Lung and Circulation, 2007, 16, S71-S82.	0.2	31
113	Effect of denervation on the content of cardiac troponin-T and cardiac troponin-I in rat skeletal muscle. Clinical Biochemistry, 2007, 40, 423-426.	0.8	8
114	Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood. Clinical Chemistry and Laboratory Medicine, 2006, 44, 1269-77.	1.4	23
115	Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. American Heart Journal, 2006, 152, 253-262.	1.2	154
116	Diagnostic and prognostic role of cardiac troponin I (cTnI) measured on the DPC Immulite. Clinical Biochemistry, 2006, 39, 692-696.	0.8	8
117	The Cost Effectiveness of Bâ€₹ype Natriuretic Peptide Measurement in the Primary Care Setting—A UK Perspective. Congestive Heart Failure, 2006, 12, 103-107.	2.0	18
118	Interpretation of Cardiac Troponin Measurements in Neonates – The Devil Is in the Details. Neonatology, 2006, 89, 194-196.	0.9	11
119	Utility of admission cardiac troponin and "Ischemia Modified Albumin" measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department. Emergency Medicine Journal, 2006, 23, 256-261.	0.4	66
120	Ischemia-Modified Albumin Concentrations Should Be Interpreted with Caution in Patients with Low Serum Albumin Concentrations. Medical Principles and Practice, 2006, 15, 322-324.	1.1	42
121	Comparison of biomarker strategies for rapid rule out of myocardial infarction in the emergency department using ACC/ESC diagnostic criteria. Annals of Clinical Biochemistry, 2006, 43, 273-280.	0.8	31
122	High Definition Contrast-Enhanced MR Imaging in Paroxysmal Nocturnal Hemoglobinuria (PNH) Suggests a High Frequency of Subclinical Thrombosis Blood, 2006, 108, 979-979.	0.6	6
123	Cardiac troponins as biomarkers of drug- and toxin-induced cardiac toxicity and cardioprotection. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 715-725.	1.5	38
124	What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?. European Heart Journal, 2005, 26, 2269-2276.	1.0	145
125	Biomarkers in Angina. Scandinavian Journal of Clinical and Laboratory Investigation, 2005, 65, 86-92.	0.6	5
126	Cardiac troponins in intensive care. Critical Care, 2005, 9, 345.	2.5	7

#	Article	IF	Citations
127	The British Cardiac Society on the redefinition of myocardial infarction: a basis for discussion. Annals of Clinical Biochemistry, 2004, 41, 258-259.	0.8	2
128	Multicenter analytical performance evaluation of the Elecsys $\hat{A}^{@}$ proBNP assay. Clinical Chemistry and Laboratory Medicine, 2004, 42, 965-72.	1.4	68
129	Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsysâ,,¢ 1010 and 2010 analysers. European Journal of Heart Failure, 2004, 6, 365-368.	2.9	141
130	Ischemia Modified Albumin Is a Sensitive Marker of Myocardial Ischemia After Percutaneous Coronary Intervention. Circulation, 2003, 107, 2403-2405.	1.6	201
131	Measurement of cardiac troponin I in striated muscle using three experimental methods. Annals of Clinical Biochemistry, 2003, 40, 244-248.	0.8	6
132	The cardiospecificity of the third-generation cTnT assay after exercise-induced muscle damage. Medicine and Science in Sports and Exercise, 2002, 34, 651-654.	0.2	34
133	The impact of biochemical tests on patient management. , 2002, , 325-333.		0
134	Cardiac troponin-I content of skeletal muscle in patients with renal failure. Clinical Biochemistry, 2002, 35, 421-423.	0.8	5
135	Cardiac Troponin T and Creatine Kinase MB Are Not Increased in Exterior Oblique Muscle of Patients with Renal Failure. Clinical Chemistry, 2001, 47, 1023-1030.	1.5	24
136	Cardiac markers in the diagnosis of acute coronary syndromes. Current Cardiology Reports, 2001, 3, 280-288.	1.3	2
137	Clinical Evaluation of the ACS:180 Cardiac Troponin I Assay. Annals of Clinical Biochemistry, 2001, 38, 509-519.	0.8	15
138	Measurement of Cardiac Troponins. Annals of Clinical Biochemistry, 2001, 38, 423-449.	0.8	218
139	Response to "Increased Creatine Kinase MB and Cardiac Troponin T with Normal Cardiac Troponin I in Metastatic Alveolar Rhabdomyosarcoma― Clinical Chemistry, 2000, 46, 432-435.	1.5	3
140	Clinical Evaluation of the First Medical Whole Blood, Point-of-Care Testing Device for Detection of Myocardial Infarction. Clinical Chemistry, 2000, 46, 1604-1609.	1.5	49
141	The need for a point of care testing: An evidence-based appraisal. Scandinavian Journal of Clinical and Laboratory Investigation, 1999, 59, 67-73.	0.6	32
142	Prospective study of the role of cardiac troponin T in patients admitted with unstable angina. BMJ: British Medical Journal, 1996, 313, 262-264.	2.4	165
143	Prognostic Significance of Admission Troponin T Concentrations in Patients With Myocardial Infarction. Circulation, 1996, 94, 1291-1297.	1.6	175
144	Measurement of Serum Troponin T, Creatine Kinase MB Isoenzyme, and Total Creatine Kinase following Arduous Physical Training. Annals of Clinical Biochemistry, 1995, 32, 450-453.	0.8	39

# ARTICLE IF CITATIONS

145 Measurement of Cardiac Troponins., 0, . 58